{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T09:05:31Z","timestamp":1767171931394,"version":"build-2238731810"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Abdosaleh Jafari","award":["93-01-68-7592"],"award-info":[{"award-number":["93-01-68-7592"]}]},{"name":"Abdosaleh Jafari","award":["93-01-68-7592"],"award-info":[{"award-number":["93-01-68-7592"]}]},{"name":"Abdosaleh Jafari","award":["93-01-68-7592"],"award-info":[{"award-number":["93-01-68-7592"]}]},{"name":"Abdosaleh Jafari","award":["93-01-68-7592"],"award-info":[{"award-number":["93-01-68-7592"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-024-11800-8","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T05:17:06Z","timestamp":1730092626000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of oral versus injectable disease modifying therapies in relapsing multiple sclerosis: a systematic review analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Mehdi","family":"Rezaee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramin","family":"Ravangard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyyed Morteza","family":"Mojtabaeian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3035-2798","authenticated-orcid":false,"given":"Abdosaleh","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"11800_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.nic.2016.12.001","volume":"27","author":"A Vidal-Jordana","year":"2017","unstructured":"Vidal-Jordana A, Montalban X. Multiple sclerosis: epidemiologic, clinical, and therapeutic aspects. Neuroimaging Clin N Am. 2017;27:195\u2013204.","journal-title":"Neuroimaging Clin N Am"},{"key":"11800_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jaut.2014.01.022","volume":"48\u201349","author":"D Karussis","year":"2014","unstructured":"Karussis D. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J Autoimmun. 2014;48\u201349:134\u201342.","journal-title":"J Autoimmun"},{"key":"11800_CR3","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12883-022-02700-7","volume":"22","author":"Z Hosseini","year":"2022","unstructured":"Hosseini Z, Homayuni A, Etemadifar M. Barriers to quality of life in patients with multiple sclerosis: a qualitative study. BMC Neurol. 2022;22:174.","journal-title":"BMC Neurol"},{"key":"11800_CR4","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L, Kaye W, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler. 2020;26:1816\u201321.","journal-title":"Mult Scler"},{"key":"11800_CR5","doi-asserted-by":"crossref","unstructured":"Holm RP, Wandall-Holm MF, Magyari M. Multiple sclerosis in Denmark (1950\u20132023): mean age, sex distribution, incidence and prevalence. Brain, 2024.","DOI":"10.1093\/brain\/awae245"},{"key":"11800_CR6","doi-asserted-by":"publisher","first-page":"102352","DOI":"10.1016\/j.msard.2020.102352","volume":"45","author":"H\u00d8 Flemmen","year":"2020","unstructured":"Flemmen H\u00d8, Simonsen CS, Berg-Hansen P, Moen SM, et al. Prevalence of multiple sclerosis in rural and urban districts in Telemark county, Norway. Multiple Scler Relat Disorders. 2020;45:102352.","journal-title":"Multiple Scler Relat Disorders"},{"key":"11800_CR7","doi-asserted-by":"publisher","first-page":"103162","DOI":"10.1016\/j.msard.2021.103162","volume":"55","author":"M Wnuk","year":"2021","unstructured":"Wnuk M, Maluchnik M, Perwieniec J, Podwojcic K, et al. Multiple sclerosis incidence and prevalence in Poland: data from administrative health claims. Multiple Scler Relat Disorders. 2021;55:103162.","journal-title":"Multiple Scler Relat Disorders"},{"key":"11800_CR8","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1136\/jnnp-2022-328932","volume":"93","author":"S Simpson-Yap","year":"2022","unstructured":"Simpson-Yap S, Atvars R, Blizzard L, van der Mei I, et al. Increasing incidence and prevalence of multiple sclerosis in the Greater Hobart cohort of Tasmania, Australia. J Neurol Neurosurg Psychiatry. 2022;93:723\u201331.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11800_CR9","doi-asserted-by":"publisher","first-page":"103119","DOI":"10.1016\/j.msard.2021.103119","volume":"54","author":"A Forouhari","year":"2021","unstructured":"Forouhari A, Taheri G, Salari M, Moosazadeh M, et al. Multiple sclerosis epidemiology in Asia and Oceania; a systematic review and meta-analysis. Multiple Scler Relat Disorders. 2021;54:103119.","journal-title":"Multiple Scler Relat Disorders"},{"key":"11800_CR10","doi-asserted-by":"publisher","first-page":"101959","DOI":"10.1016\/j.msard.2020.101959","volume":"40","author":"M Etemadifar","year":"2020","unstructured":"Etemadifar M, Nikanpour Y, Neshatfar A, Mansourian M, et al. Incidence and prevalence of multiple sclerosis in persian gulf area: a systematic review and meta-analysis. Mult Scler Relat Disord. 2020;40:101959.","journal-title":"Mult Scler Relat Disord"},{"key":"11800_CR11","doi-asserted-by":"publisher","first-page":"102963","DOI":"10.1016\/j.msard.2021.102963","volume":"52","author":"M Zeineddine","year":"2021","unstructured":"Zeineddine M, Hajje AA, Hussein A, Ayoubi NE, et al. Epidemiology of multiple sclerosis in Lebanon: a rising prevalence in the Middle East. Multiple Scler Relat Disorders. 2021;52:102963.","journal-title":"Multiple Scler Relat Disorders"},{"key":"11800_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12883-020-1629-3","volume":"20","author":"M AlJumah","year":"2020","unstructured":"AlJumah M, Bunyan R, Al Otaibi H, Al Towaijri G, et al. Rising prevalence of multiple sclerosis in Saudi Arabia, a descriptive study. BMC Neurol. 2020;20:49.","journal-title":"BMC Neurol"},{"key":"11800_CR13","doi-asserted-by":"publisher","first-page":"104557","DOI":"10.1016\/j.msard.2023.104557","volume":"71","author":"A Moghtaderi","year":"2023","unstructured":"Moghtaderi A, Shahidi-Pourakbari M, Izadi S, Khosravi A, et al. Ongoing increase in incidence and prevalence of multiple sclerosis in south-eastern Iran: a three decade study. Multiple Scler Relat Disorders. 2023;71:104557.","journal-title":"Multiple Scler Relat Disorders"},{"key":"11800_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.32598\/CJNS.8.29.4","volume":"8","author":"M Dastoorpoor","year":"2022","unstructured":"Dastoorpoor M, Khodadadi N, Majdinasab N, Soltani M, et al. The Time-trend of multiple sclerosis incidence and prevalence in Khuzestan Province, Iran. Casp J Neurol Sci. 2022;8:104\u201316.","journal-title":"Casp J Neurol Sci"},{"key":"11800_CR15","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s10072-021-05280-5","volume":"43","author":"M Sarmadi","year":"2022","unstructured":"Sarmadi M, Saravani H, Azizi O, Najafi F, et al. Temporal trends of incidence and prevalence of multiple sclerosis in Razavi Khorasan Province, Northeast Iran. Neurol Sci. 2022;43:583\u201391.","journal-title":"Neurol Sci"},{"key":"11800_CR16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10072-021-05750-w","volume":"43","author":"O Mirmosayyeb","year":"2022","unstructured":"Mirmosayyeb O, Shaygannejad V, Bagherieh S, Hosseinabadi AM, et al. Prevalence of multiple sclerosis (MS) in Iran: a systematic review and meta-analysis. Neurol Sci. 2022;43:233\u201341.","journal-title":"Neurol Sci"},{"key":"11800_CR17","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/B978-0-444-52001-2.00020-0","volume":"122","author":"DS Goodin","year":"2014","unstructured":"Goodin DS. Glucocorticoid treatment of multiple sclerosis. Handb Clin Neurol. 2014;122:455\u201364.","journal-title":"Handb Clin Neurol"},{"key":"11800_CR18","unstructured":"National Multiple Sclerosis Society.Medications for Treating MS. Available from URL: http:\/\/www.nationalmssociety.org\/Treating-MS\/Medications."},{"key":"11800_CR19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.4103\/0972-2327.58280","volume":"12","author":"PK Coyle","year":"2009","unstructured":"Coyle PK. Disease-modifying agents in multiple sclerosis. Ann Indian Acad Neurol. 2009;12:273\u201382.","journal-title":"Ann Indian Acad Neurol"},{"key":"11800_CR20","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2165\/11207350-000000000-00000","volume":"25","author":"LJ Scott","year":"2011","unstructured":"Scott LJ. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis. CNS Drugs. 2011;25:673\u201398.","journal-title":"CNS Drugs"},{"key":"11800_CR21","first-page":"519","volume":"7","author":"C Warnke","year":"2011","unstructured":"Warnke C, St\u00fcve O, Hartung HP, Fogdell-Hahn A, et al. Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2011;7:519\u201327.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"11800_CR22","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40120-021-00320-w","volume":"11","author":"N Frahm","year":"2022","unstructured":"Frahm N, Fneish F, Ellenberger D, Flachenecker P, et al. Therapy switches in Fingolimod-treated patients with multiple sclerosis: long-term experience from the German MS Registry. Neurol Ther. 2022;11:319\u201336.","journal-title":"Neurol Ther"},{"key":"11800_CR23","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/brain\/awl007","volume":"129","author":"C Confavreux","year":"2006","unstructured":"Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129:606\u201316.","journal-title":"Brain"},{"key":"11800_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/BF02999222","volume":"14","author":"MA De Judicibus","year":"2007","unstructured":"De Judicibus MA, McCabe MP. The impact of the financial costs of multiple sclerosis on quality of life. Int J Behav Med. 2007;14:3\u201311.","journal-title":"Int J Behav Med"},{"key":"11800_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.msard.2019.02.006","volume":"30","author":"Y Kim","year":"2019","unstructured":"Kim Y, Krause TM, Blum P, Freeman L. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis. Mult Scler Relat Disord. 2019;30:69\u201375.","journal-title":"Mult Scler Relat Disord"},{"key":"11800_CR26","doi-asserted-by":"crossref","unstructured":"Yamamoto D, Campbell JD. Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature. Autoimmune Dis. 2012;2012:784364.","DOI":"10.1155\/2012\/784364"},{"key":"11800_CR27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40258-013-0034-0","volume":"11","author":"A Hawton","year":"2013","unstructured":"Hawton A, Shearer J, Goodwin E, Green C. Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis. Appl Health Econ Health Policy. 2013;11:331\u201341.","journal-title":"Appl Health Econ Health Policy"},{"key":"11800_CR28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s40273-013-0063-4","volume":"31","author":"JP Thompson","year":"2013","unstructured":"Thompson JP, Abdolahi A, Noyes K. Modelling the cost effectiveness of disease-modifying treatments for multiple sclerosis: issues to consider. PharmacoEconomics. 2013;31:455\u201369.","journal-title":"PharmacoEconomics"},{"key":"11800_CR29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40273-017-0577-2","volume":"36","author":"S Iannazzo","year":"2018","unstructured":"Iannazzo S, Iliza AC, Perrault L. Disease-Modifying therapies for multiple sclerosis: a systematic literature review of cost-effectiveness studies. PharmacoEconomics. 2018;36:189\u2013204.","journal-title":"PharmacoEconomics"},{"key":"11800_CR30","first-page":"68","volume":"44","author":"CE Navarro","year":"2020","unstructured":"Navarro CE, Ord\u00f3\u00f1ez-Callamand E, Alzate JP. Disease modifying therapies in multiple sclerosis: cost-effectiveness systematic review. Farm Hosp. 2020;44:68\u201376.","journal-title":"Farm Hosp"},{"key":"11800_CR31","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s40120-021-00264-1","volume":"10","author":"A Wiyani","year":"2021","unstructured":"Wiyani A, Badgujar L, Khurana V, Adlard N. How have economic evaluations in relapsing multiple sclerosis evolved over time? A systematic literature review. Neurol Ther. 2021;10:557\u201383.","journal-title":"Neurol Ther"},{"key":"11800_CR32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00415-020-10362-z","volume":"269","author":"CG Chisari","year":"2022","unstructured":"Chisari CG, Sgarlata E, Arena S, Toscano S, et al. Rituximab for the treatment of multiple sclerosis: a review. J Neurol. 2022;269:159\u201383.","journal-title":"J Neurol"},{"key":"11800_CR33","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/joim.13215","volume":"289","author":"F Piehl","year":"2021","unstructured":"Piehl F. Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis. J Intern Med. 2021;289:771\u201391.","journal-title":"J Intern Med"},{"key":"11800_CR34","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/WCO.0000000000001063","volume":"35","author":"BAC Cree","year":"2022","unstructured":"Cree BAC, Hartung HP, Barnett M. New drugs for multiple sclerosis: new treatment algorithms. Curr Opin Neurol. 2022;35:262\u201370.","journal-title":"Curr Opin Neurol"},{"key":"11800_CR35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/00005650-200301000-00007","volume":"41","author":"CF Chiou","year":"2003","unstructured":"Chiou CF, Hay JW, Wallace JF, Bloom BS, et al. Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care. 2003;41:32\u201344.","journal-title":"Med Care"},{"key":"11800_CR36","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/1471-0528.17012","volume":"129","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, Briggs AH, et al. Consolidated Health Economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BJOG. 2022;129:336\u201344.","journal-title":"BJOG"},{"key":"11800_CR37","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic evaluation publication Guidelines Good Reporting practices Task Force. Value Health. 2013;16:231\u201350.","journal-title":"Value Health"},{"key":"11800_CR38","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12913-022-07595-1","volume":"22","author":"BS Bagepally","year":"2022","unstructured":"Bagepally BS, Chaikledkaew U, Chaiyakunapruk N, Attia J, et al. Meta-analysis of economic evaluation studies: data harmonisation and methodological issues. BMC Health Serv Res. 2022;22:202.","journal-title":"BMC Health Serv Res"},{"key":"11800_CR39","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3111\/13696998.2012.693553","volume":"15","author":"S Lee","year":"2012","unstructured":"Lee S, Baxter DC, Limone B, Roberts MS, et al. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States. J Med Econ. 2012;15:1088\u201396.","journal-title":"J Med Econ"},{"key":"11800_CR40","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s40263-014-0207-x","volume":"29","author":"XK Zhang","year":"2015","unstructured":"Zhang XK, Hay JW, Niu XL. Cost effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-beta(1a) in relapsing-remitting multiple sclerosis. CNS Drugs. 2015;29:71\u201381.","journal-title":"CNS Drugs"},{"key":"11800_CR41","doi-asserted-by":"crossref","unstructured":"Chevalier J, Chamoux C, Hamm\u00e8s F, Chicoye A. Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective. PLoS One. 2016;11(3):e0150703.","DOI":"10.1371\/journal.pone.0150703"},{"key":"11800_CR42","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3111\/13696998.2015.1135805","volume":"19","author":"J Mauskopf","year":"2016","unstructured":"Mauskopf J, Fay M, Iyer R, Sarda S, et al. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States. J Med Econ. 2016;19:432\u201342.","journal-title":"J Med Econ"},{"key":"11800_CR43","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3111\/13696998.2016.1164174","volume":"19","author":"WQ Su","year":"2016","unstructured":"Su WQ, Kansal A, Vicente C, Deniz B, et al. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada. J Med Econ. 2016;19:718\u201327.","journal-title":"J Med Econ"},{"key":"11800_CR44","doi-asserted-by":"publisher","first-page":"433","DOI":"10.5144\/0256-4947.2017.433","volume":"37","author":"MF Alsaqa\u2019aby","year":"2017","unstructured":"Alsaqa\u2019aby MF, Vaidya V, Khreis N, Al Khairallah T, et al. Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia. Ann Saudi Med. 2017;37:433\u201343.","journal-title":"Ann Saudi Med"},{"key":"11800_CR45","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1080\/13696998.2017.1345748","volume":"20","author":"SM Montgomery","year":"2017","unstructured":"Montgomery SM, Kusel J, Nicholas R, Adlard N. Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility. J Med Econ. 2017;20:962\u201373.","journal-title":"J Med Econ"},{"key":"11800_CR46","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1080\/13696998.2016.1276070","volume":"20","author":"SM Montgomery","year":"2017","unstructured":"Montgomery SM, Maruszczak MJ, Slater D, Kusel J, et al. A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK. J Med Econ. 2017;20:474\u201382.","journal-title":"J Med Econ"},{"key":"11800_CR47","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.clinthera.2017.01.028","volume":"39","author":"E Soini","year":"2017","unstructured":"Soini E, Joutseno J, Sumelahti ML. Cost-utility of first-line disease-modifying treatments for relapsing\u2013remitting multiple sclerosis. Clin Ther. 2017;39:537\u2013e55710.","journal-title":"Clin Ther"},{"key":"11800_CR48","doi-asserted-by":"publisher","first-page":"p584","DOI":"10.1017\/S0266462318003604","volume":"34","author":"C Chanatittarat","year":"2018","unstructured":"Chanatittarat C, Chaikledkaew U, Prayoonwiwat N, Siritho S, et al. Cost-utility analysis of multiple sclerosis treatment in Thailand. Int J Technol Assess Health Care. 2018;34:p584\u2013592.","journal-title":"Int J Technol Assess Health Care"},{"key":"11800_CR49","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1080\/13696998.2018.1461630","volume":"21","author":"R Hettle","year":"2018","unstructured":"Hettle R, Harty G, Wong SL. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England. J Med Econ. 2018;21:676\u201386.","journal-title":"J Med Econ"},{"key":"11800_CR50","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s40263-018-0566-9","volume":"32","author":"M Zimmermann","year":"2018","unstructured":"Zimmermann M, Brouwer E, Tice J, Seidner M, et al. Disease-Modifying therapies for Relapsing-Remitting and Primary Progressive multiple sclerosis: a cost-utility analysis. CNS Drugs. 2018;32:1145\u201357.","journal-title":"CNS Drugs"},{"key":"11800_CR51","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jval.2018.08.011","volume":"22","author":"V Chirikov","year":"2019","unstructured":"Chirikov V, Ma I, Joshi N, Patel D, et al. Cost-effectiveness of Alemtuzumab in the treatment of relapsing forms of multiple sclerosis in the United States. Value Health. 2019;22:168\u201376.","journal-title":"Value Health"},{"key":"11800_CR52","first-page":"61","volume-title":"The Value and Sustainability of Ocrelizumab in Relapsing Multiple Sclerosis: A Cost-Effectiveness and Budget Impact Analysis","author":"PA Cortesi","year":"2019","unstructured":"Cortesi PA, Paolicelli D, Capobianco M, Cozzolino P, et al. The Value and sustainability of Ocrelizumab in Relapsing multiple sclerosis: a cost-effectiveness and Budget Impact Analysis. Volume 20. Farmeconomia-Health Economics and Therapeutic Pathways; 2019. pp. 61\u201372."},{"key":"11800_CR53","doi-asserted-by":"publisher","first-page":"490","DOI":"10.18553\/jmcp.2019.25.4.490","volume":"25","author":"LH Hua","year":"2019","unstructured":"Hua LH, Hersh CM, Morten P, Kusel J, et al. The impact of price reductions after loss of exclusivity in a cost-effectiveness analysis: Fingolimod versus interferon beta-1a for the treatment of relapsing-remitting multiple sclerosis. J Managed Care Specialty Pharm. 2019;25:490\u2013b498.","journal-title":"J Managed Care Specialty Pharm"},{"key":"11800_CR54","doi-asserted-by":"publisher","first-page":"73","DOI":"10.7175\/fe.v20i1.1437","volume":"20","author":"LG Mantovani","year":"2019","unstructured":"Mantovani LG, Furneri G, Bitonti R, Cortesi P, et al. Cost-effectiveness analysis of Dimethyl Fumarate in the treatment of relapsing remitting multiple sclerosis: an Italian societal perspective. Farmeconomia-Health Econ Therapeutic Pathways. 2019;20:73\u201386.","journal-title":"Farmeconomia-Health Econ Therapeutic Pathways"},{"key":"11800_CR55","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s40258-019-00500-8","volume":"17","author":"RE Michels","year":"2019","unstructured":"Michels RE, de Fransesco M, Mahajan K, Hengstman GJD, et al. Cost effectiveness of Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis in the Netherlands. Appl Health Econ Health Policy. 2019;17:857\u201373.","journal-title":"Appl Health Econ Health Policy"},{"key":"11800_CR56","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/13696998.2018.1560750","volume":"22","author":"M Rezaee","year":"2019","unstructured":"Rezaee M, Izadi S, Keshavarz K, Borhanihaghighi A, et al. Fingolimod versus Natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran. J Med Econ. 2019;22:297\u2013305.","journal-title":"J Med Econ"},{"key":"11800_CR57","doi-asserted-by":"publisher","DOI":"10.1177\/2284240319838524","volume-title":"The cost-effectiveness of alemtuzumab in the management of relapse-remitting multiple sclerosis in Italy","author":"S Stanisic","year":"2019","unstructured":"Stanisic S, Bertolotto A, Berto P, Di Procolo P, et al. The cost-effectiveness of alemtuzumab in the management of relapse-remitting multiple sclerosis in Italy. Global & Regional Health Technology Assessment; 2019."},{"key":"11800_CR58","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/13696998.2018.1556668","volume":"22","author":"E Walter","year":"2019","unstructured":"Walter E, Berger T, Bajer-Kornek B, Deisenhammer F. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria. J Med Econ. 2019;22:226\u201337.","journal-title":"J Med Econ"},{"key":"11800_CR59","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40261-019-00750-3","volume":"39","author":"Y Xu","year":"2019","unstructured":"Xu Y, Mao NY, Chirikov V, Du F, et al. Cost-effectiveness of Teriflunomide compared to Interferon Beta-1b for relapsing multiple sclerosis patients in China. Clin Drug Investig. 2019;39:331\u201340.","journal-title":"Clin Drug Investig"},{"key":"11800_CR60","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.vhri.2019.08.481","volume":"23","author":"P Lasalvia","year":"2020","unstructured":"Lasalvia P, Hern\u00e1ndez F, Casta\u00f1eda-Cardona C, Cuestas JA, et al. Cost-effectiveness of Natalizumab compared with Fingolimod for relapsing-remitting multiple sclerosis treatment in Colombia. Value Health Reg Issues. 2020;23:13\u20138.","journal-title":"Value Health Reg Issues"},{"key":"11800_CR61","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1080\/13696998.2020.1840138","volume":"23","author":"HR Nakhaipour","year":"2020","unstructured":"Nakhaipour HR, Vudumula U, Khurana V, S\u00e9bire G, et al. Cost-effectiveness of fingolimod versus interferon-\u03b21a for the treatment of pediatric-onset multiple sclerosis in Canada. J Med Econ. 2020;23:1525\u201333.","journal-title":"J Med Econ"},{"key":"11800_CR62","first-page":"146","volume":"20","author":"N Ayati","year":"2021","unstructured":"Ayati N, Fleifel L, Sharifi S, Sahraian MA, et al. Cladribine tablets are a cost-effective strategy in high-disease activity relapsing multiple sclerosis patients in Iran. Curr J Neurol. 2021;20:146\u201353.","journal-title":"Curr J Neurol"},{"key":"11800_CR63","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.vhri.2021.03.007","volume":"25","author":"S Bohlega","year":"2021","unstructured":"Bohlega S, Elboghdady A, Al-Johani A, Mahajan K, et al. Economic evaluation of Cladribine tablets in patients with High Disease activity\u2013relapsing-remitting multiple sclerosis in the Kingdom of Saudi Arabia. Value Health Reg Issues. 2021;25:189\u201395.","journal-title":"Value Health Reg Issues"},{"key":"11800_CR64","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s41669-021-00282-7","volume":"5","author":"MA Espinoza","year":"2021","unstructured":"Espinoza MA, Rojas R, Zaupa A, Balmaceda C. A model-based economic evaluation of Cladribine Versus Alemtuzumab, Ocrelizumab and Natalizumab for the treatment of relapsing-remitting multiple sclerosis with High Disease Activity in Chile. PharmacoEconomics - Open. 2021;5:635\u201347.","journal-title":"PharmacoEconomics - Open"},{"key":"11800_CR65","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s40273-021-01023-8","volume":"39","author":"N Schur","year":"2021","unstructured":"Schur N, Gudala K, Vudumula U, Vadapalle S, et al. Cost effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the treatment of adult patients with secondary progressive multiple sclerosis with active disease in Switzerland. PharmacoEconomics. 2021;39:563\u201377.","journal-title":"PharmacoEconomics"},{"key":"11800_CR66","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s41669-022-00363-1","volume":"6","author":"M Baharnoori","year":"2022","unstructured":"Baharnoori M, Bhan V, Clift F, Thomas K, et al. Cost-effectiveness analysis of Ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada. PharmacoEconomics - Open. 2022;6:859\u201370.","journal-title":"PharmacoEconomics - Open"},{"key":"11800_CR67","volume-title":"Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal","author":"P Martins","year":"2022","unstructured":"Martins P, Vandewalle B, F\u00e9lix J, Capela CM, et al. Cost-effectiveness analysis of Ocrelizumab for the treatment of relapsing and Primary Progressive multiple sclerosis in Portugal. PharmacoEconomics - Open; 2022."},{"key":"11800_CR68","first-page":"67","volume-title":"Economic evaluation of cladribine tablets in high disease activity (HDA) relapsing multiple sclerosis (RMS) patients in Lebanon","author":"M Matni","year":"2022","unstructured":"Matni M, Yamout B, Koussa S, Khamis C, et al. Economic evaluation of cladribine tablets in high disease activity (HDA) relapsing multiple sclerosis (RMS) patients in Lebanon. Multiple Sclerosis and Related Disorders; 2022. p. 67."},{"key":"11800_CR69","doi-asserted-by":"publisher","first-page":"e1230","DOI":"10.1002\/cl2.1230","volume":"18","author":"NR Haddaway","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev. 2022;18:e1230.","journal-title":"Campbell Syst Rev."}],"updated-by":[{"DOI":"10.1186\/s12913-025-12280-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000}}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-024-11800-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-024-11800-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-024-11800-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T16:12:34Z","timestamp":1737648754000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-024-11800-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["11800"],"URL":"https:\/\/doi.org\/10.1186\/s12913-024-11800-8","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"21 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12913-025-12280-0","URL":"https:\/\/doi.org\/10.1186\/s12913-025-12280-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data are collected and handled in accordance with the relevant privacy protection guidelines. According to Iran law, the study did not fall under the remit of the Medical Research Involving Human Subjects Act and no approval by a medical ethics committee was necessary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1288"}}